Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis

• Published in: PLoS medicine Vol. 18; no. 6; p. e1003664
• Main Authors: Gosmann, Natan Pereira, Costa, Marianna de Abreu, Jaeger, Marianna de Barros, Motta, Luis Souza, Frozi, Júlia, Spanemberg, Lucas, Manfro, Gisele Gus, Cuijpers, Pim, Pine, Daniel Samuel, Salum, Giovanni Abrahão
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 10-06-2021; Public Library of Science (PLoS)
• Subjects: Antidepressants; Anxiety; Anxiety disorders; Biology and Life Sciences; Catecholamines; Clinical trials; Data analysis; Diagnosis; Drug therapy; Emotional disorders; Estimates; Fear & phobias; Intervention; Life span; Medicine and Health Sciences; Mental disorders; Meta-analysis; Mood disorders; Noradrenaline; Norepinephrine; Obsessive compulsive disorder; Patient outcomes; Patients; Pharmaceutical industry; Physical Sciences; Placebos; Post-traumatic stress disorder; Psychopathology; Psychotherapy; Random variables; Research and Analysis Methods; Serotonin; Serotonin agonists; Serotonin uptake inhibitors; Social anxiety; Stress; Brazil
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1003664

Anxiety, obsessive-compulsive, and stress-related disorders frequently co-occur, and patients often present symptoms of several domains. Treatment involves the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), but data on comparative efficacy and acceptability are lacking. We aimed to compare the efficacy of SSRIs, SNRIs, and placebo in multiple symptom domains in patients with these diagnoses over the lifespan through a 3-level network meta-analysis. We searched for published and unpublished randomized controlled trials that aimed to assess the efficacy of SSRIs or SNRIs in participants (adults and children) with diagnosis of any anxiety, obsessive-compulsive, or stress-related disorder in MEDLINE, PsycINFO, Embase, and Cochrane Library from inception to 23 April 2015, with an update on 11 November 2020. We supplemented electronic database searches with manual searches for published and unpublished randomized controlled trials registered in publicly accessible clinical trial registries and pharmaceutical companies' databases. No restriction was made regarding comorbidities with any other mental disorder, participants' age and sex, blinding of participants and researchers, date of publication, or study language. The primary outcome was the aggregate measure of internalizing symptoms of these disorders. Secondary outcomes included specific symptom domains and treatment discontinuation rate. We estimated standardized mean differences (SMDs) with 3-level network meta-analysis with random slopes by study for medication and assessment instrument. Risk of bias appraisal was performed using the Cochrane Collaboration's risk of bias tool. This study was registered in PROSPERO (CRD42017069090). We analyzed 469 outcome measures from 135 studies (n = 30,245). All medications were more effective than placebo for the aggregate measure of internalizing symptoms (SMD -0.56, 95% CI -0.62 to -0.51, p < 0.001), for all symptom domains, and in patients from all diagnostic categories. We also found significant results when restricting to the most used assessment instrument for each diagnosis; nevertheless, this restriction led to exclusion of 72.71% of outcome measures. Pairwise comparisons revealed only small differences between medications in efficacy and acceptability. Limitations include the moderate heterogeneity found in most outcomes and the moderate risk of bias identified in most of the trials. In this study, we observed that all SSRIs and SNRIs were effective for multiple symptom domains, and in patients from all included diagnostic categories. We found minimal differences between medications concerning efficacy and acceptability. This three-level network meta-analysis contributes to an ongoing discussion about the true benefit of antidepressants with robust evidence, considering the significantly larger quantity of data and higher statistical power when compared to previous studies. The 3-level approach allowed us to properly assess the efficacy of these medications on internalizing psychopathology, avoiding potential biases related to the exclusion of information due to distinct assessment instruments, and to explore the multilevel structure of transdiagnostic efficacy.